Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure

The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson"s disease according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria
• Levodopa induced dyskinesia

Exclusion Criteria:

• Previous surgery for Parkinson's disease
• Any current or history of heart condition or increased pro-arrhythmic risk
• Severe or ongoing unstable medical condition